Atossa Therapeutics Inc ATOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
-
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
-
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
-
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
-
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
-
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
-
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
-
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
Trading Information
- Previous Close Price
- $2.40
- Day Range
- $2.37–2.49
- 52-Week Range
- $1.70–19.35
- Bid/Ask
- $2.43 / $2.48
- Shares Outstanding
- 9.97M
- Market Cap
- $24.24M
- Volume/Avg
- 26,603 / 153,609
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
Valuation
|
Metric
|
ATOS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.68 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATOS
|
|---|---|
Quick Ratio | 4.25 |
Current Ratio | 4.92 |
Interest Coverage | — |
Quick Ratio
ATOS
Profitability
|
Metric
|
ATOS
|
|---|---|
Return on Assets (Normalized) | −62.47% |
Return on Equity (Normalized) | −71.78% |
Return on Invested Capital (Normalized) | −75.84% |
Return on Assets
ATOS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>wk#FMn | LOCK|<#k& | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!q&%B?# | LOCK|LQSY | $71B | |||
| argenx SE ADR
ARGX
| LOCK|^K%&>M | LOCK|Zg | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|MZG?rn | LOCK|h>@ | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|sTV>Ms | LOCK|g?cy> | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|KCcW?>!& | LOCK|>CDkP | $26B | |||
| Moderna Inc
MRNA
| LOCK|Prhm%! | LOCK|%v | $24B | |||
| Incyte Corp
INCY
| LOCK|$py@LP< | LOCK|pn | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?K^$F^ | LOCK|%<n | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|TGx>ny | LOCK|%H | $16B |
United States